Landos Biopharma Inc expected to post a loss of $1.10 a share - Earnings Preview

Landos Biopharma

07/08/2023 19:34

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show no
change in quarterly revenue when it reports  results on August 9
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Landos Biopharma
Inc is
for a loss of $1.10 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $10​, above​ its last closing price of $3.98. ​​​

This summary was machine generated August 7 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated